MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijid.2006.09.010

Медицинская библиотека · International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2007

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

Betancourt Arístides Aguilar, Delgado C A González, Estévez Z Cinza, Martínez J Cabrera, Ríos G Véliz, Aureoles-Roselló S R Moreno, Zaldívar R Alemán, Guzmán M Alonso, Baile N Figueroa, Reyes P A Días, Ruano L Olivera, Fernández A Correa, Lobaina-Matos Y, Fernández A Delahanty, Madrazo A I Juvier, Martínez M I Alonso, Baños M Lago, Alvarez N Puble, Baldo M David, Mestre R E Soto, Pérez M V Pérez, Martínez M E Peña, Escobar D Acosta, Guanche M J Cerna, Cáceres L Mila, Betancourt R Sánchez, Rando E Hardy, Nieto G E Guillén, González V L Muzio, Rubido J C Aguilar

Клиническое исследование I фазыСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The nasal vaccine candidate (NASVAC), comprising hepatitis B virus (HBV) surface (HBsAg) and core antigens (HBcAg), has been shown to be highly immunogenic in animal models.

METHODS

A phase I double-blinded, placebo-controlled randomized clinical trial was carried out in 19 healthy male adults with no serologic markers of immunity/infection to HBV. This study was aimed at exploring the safety and immunogenic profile of nasal co-administration of both HBV recombinant antigens. The trial was performed according to Good Clinical Practice guidelines. Participants ranged in age from 18 to 45 years and were randomly allocated to receive a mixture of 50 microg HBsAg and 50 microg HBcAg or 0.9% physiologic saline solution, as a placebo, via nasal spray in a five-dose schedule at 0, 7, 15, 30, and 60 days. A total volume of 0.5 ml was administered in two dosages of 125 microl per nostril. Adverse events were actively recorded 1 h, 6 h, 12 h, 24 h, 48 h, 72 h, 7 days and 30 days after each dose. Anti-HBs and anti-HBc titers were evaluated using corresponding ELISA kits at days 30 and 90.

RESULTS

The vaccine candidate was safe and well tolerated. Adverse reactions included sneezing (34.1%), rhinorrhea (12.2%), nasal stuffiness (9.8%), palate itching (9.8%), headache (9.8%), and general malaise (7.3%). These reactions were all self-limiting and mild in intensity. No severe or unexpected events were recorded during the trial. The vaccine elicited anti-HBc seroconversion in 100% of subjects as early as day 30 of the immunization schedule, while a seroprotective anti-HBs titer (>or=10 IU/l) was at a maximum at day 90 (75%). All subjects in the placebo group remained seronegative during the trial.

CONCLUSION

The HBsAg-HBcAg vaccine candidate was safe, well tolerated and immunogenic in this phase I study in healthy adults. To our knowledge, this is the first demonstration of safety and immunogenicity for a nasal vaccine candidate comprising HBV antigens.

Для цитирования: Betancourt Arístides Aguilar, Delgado C A González, Estévez Z Cinza, Martínez J Cabrera, Ríos G Véliz, Aureoles-Roselló S R Moreno, Zaldívar R Alemán, Guzmán M Alonso, Baile N Figueroa, Reyes P A Días, Ruano L Olivera, Fernández A Correa, Lobaina-Matos Y, Fernández A Delahanty, Madrazo A I Juvier, Martínez M I Alonso, Baños M Lago, Alvarez N Puble, Baldo M David, Mestre R E Soto, Pérez M V Pérez, Martínez M E Peña, Escobar D Acosta, Guanche M J Cerna, Cáceres L Mila, Betancourt R Sánchez, Rando E Hardy, Nieto G E Guillén, González V L Muzio, Rubido J C Aguilar. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2007. DOI: 10.1016/j.ijid.2006.09.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.